This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why MetLife (MET) Could Be a Top Value Stock Pick
by Zacks Equity Research
MetLife (MET) is a pretty good value pick, as it has decent revenue metrics to back up its earnings, and is seeing solid earnings estimate revisions as well.
Brown & Brown's Strategic Efforts Impress, Rising Costs Ail
by Zacks Equity Research
Brown & Brown's (BRO) sustained operational performance and a solid capital backup impress but rising expenses bother.
Hartford Financial Streamlines Business With Talcott Sale
by Zacks Equity Research
Hartford Financial's (HIG) Talcott Resolution segment has been underperforming for quite a long time. Divestiture of this unit is expected to improve the company's overall financial health.
Arthur J. Gallagher's Buyout to Boost Brokerage Services
by Zacks Equity Research
Arthur J. Gallagher (AJG) continues with its inorganic growth strategy riding on Weiss Insurance buyout.
Radian (RDN) Shows Potential to Grow: Apt to Buy the Stock?
by Zacks Equity Research
Radian (RDN) holds immense potential on the back of growth projections and favorable fundamentals.
Here's Why You Should Buy Prudential Financial (PRU) Now
by Zacks Equity Research
Prudential Financial's (PRU) compelling product portfolio plus greater scale and broader distribution capabilities position it well for long-term growth.
Radian Divests Clayton EuroRisk to Focus on Core Service
by Zacks Equity Research
Radian's (RDN) divestiture of Clayton EuroRisk reflects its restructuring efforts to intensify focus on core business.
Top Stock Reports for Apple, Facebook & MetLife
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), Facebook (FB) and MetLife (MET).
AIG Misses on Q3 Earnings Due to Weather, to Puff Up Reserves
by Zacks Equity Research
AIG's third-quarter earnings suffered from catastrophe losses, partly offset by reduction in expense.
MetLife (MET) Q3 Earnings Top on Volume Growth, OK's Buyback
by Zacks Equity Research
MetLife's (MET) Q3 earnings reflect volume growth. The board of directors also approves a $2 billion buyback program. The company also is on track to return $4.5 billion to shareholders in 2017.
Metlife vs. Prudential: Which is Better Ahead of Q3 Earnings?
by Swarup Gupta
With sector majors Prudential and MetLife, both scheduled to report on Nov 1, this may be a good time to consider which of these is a better stock.
MetLife (MET) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
MetLife's (MET) third-quarter earnings are likely to benefit on higher contribution from its U.S business coupled with expense management initiatives and capital management.
MetLife (MET) and Units Receive Rating Action From A.M Best
by Zacks Equity Research
MetLife's (MET) business strategies have helped it sharpen its competitive edge and operational efficiency aided it to deliver strong results. It has received favorable ratings from several rating agencies on the back of these positives.
MetLife (MET) Expands Coverage to Include Diabetic Patients
by Zacks Equity Research
The expansion of coverage by MetLife Hong Kong, a wholly owned subsidiary of MetLife (MET), intends to make medical facilities easily accessible for diabetic patients.
MetLife's Logan Circle Buy to Boost Investment Management
by Zacks Equity Research
MetLife's (MET) $250 million buyout of Logan Circle primarily aims at strengthening the acquirer's investment management expertise.
Why Is MetLife (MET) Down 11.5% Since the Last Earnings Report?
by Zacks Equity Research
MetLife (MET) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
Insurance Stocks to Endure the Wrath of Hurricane Harvey
by Zacks Equity Research
Property and casualty stocks might witness an earnings drain due to hurricane Harvey, but the event is expected to benefit them in the form of increased premium prices.
Forget MetLife (MET), Buy These 3 Insurance Stocks Instead
by Zacks Equity Research
MetLife's (MET) declining revenues from low premiums, fees and other revenues, macroeconomic factors, and low return on equity make it an unattractive stock now.
The Zacks Analyst Blog Highlights: CVS Health, Marriott, Enbridge, MetLife and Aon
by Zacks Equity Research
The Zacks Analyst Blog Highlights: CVS Health, Marriott, Enbridge, MetLife and Aon
MetLife Suffers From Declining Revenues, Spinoff Charges
by Zacks Equity Research
MetLife's (MET) declining revenues, low premiums, fees and other revenues continue to bother.
Top Stock Reports for CVS Health, Marriott & Enbridge
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including CVS Health (CVS), Marriott (MAR), and Enbridge (ENB).
Are Options Traders Betting on a Big Move in MetLife (MET) Stock?
by Zacks Equity Research
Investors in MetLife (MET) need to pay close attention to the stock based on moves in the options market lately.
AIG Q2 Earnings Beat as Restructuring Initiatives Pay Off
by Zacks Equity Research
American International Group Inc.'s (AIG) second-quarter results benefit from favorable performance by its consumer business, cost control efforts and share buyback.
MetLife (MET) Earnings Beat Estimates in Q2, Improve Y/Y
by Zacks Equity Research
MetLife's (MET) solid Q2 results were driven by the strong performance of all the segments.
MetLife (MET) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Metlife's (MET) second-quarter earnings may gain from higher sales in group benefit and efficient capital management. Derivative losses and foreign exchange volatility may hurt.